UK’s pharma sector votes for post-Brexit clarity under new government
As the 4 July election approaches, the UK pharmaceutical sector wants the new government to prioritise the UK’s commercial clinical landscape.
02 July 2024
02 July 2024
As the 4 July election approaches, the UK pharmaceutical sector wants the new government to prioritise the UK’s commercial clinical landscape.
Advances in automation in T-cell production are beginning to help make life-changing therapies more accessible to a growing number of patients in oncology and beyond.
This is the second hit this year to Rocket’s approval plans for the genel therapy Kresladi.
Opevesostat will now be globally developed and commercialised exclusively by MSD, with Orion set to receive milestone payments.
The Phase III data for J&J’s nipocalimab shows the antibody's efficacy in improving symptoms of myasthenia gravis.
The submission for sipavibart is based on positive outcomes from the Phase III SUPERNOVA clinical trial.
On granting approval for HMTM, the UK could become the first country to offer this oral treatment.
The preclinical data was presented at the European Academy of Neurology (EAN) 2024 Congress in Helsinki, Finland.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.